JP2018526412A5 - - Google Patents

Download PDF

Info

Publication number
JP2018526412A5
JP2018526412A5 JP2018512858A JP2018512858A JP2018526412A5 JP 2018526412 A5 JP2018526412 A5 JP 2018526412A5 JP 2018512858 A JP2018512858 A JP 2018512858A JP 2018512858 A JP2018512858 A JP 2018512858A JP 2018526412 A5 JP2018526412 A5 JP 2018526412A5
Authority
JP
Japan
Prior art keywords
composition
hgf
hgf agent
medicament
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018512858A
Other languages
English (en)
Japanese (ja)
Other versions
JP6929273B2 (ja
JP2018526412A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/050945 external-priority patent/WO2017044743A1/en
Publication of JP2018526412A publication Critical patent/JP2018526412A/ja
Publication of JP2018526412A5 publication Critical patent/JP2018526412A5/ja
Priority to JP2021130457A priority Critical patent/JP2021181472A/ja
Application granted granted Critical
Publication of JP6929273B2 publication Critical patent/JP6929273B2/ja
Priority to JP2023179927A priority patent/JP2023179739A/ja
Priority to JP2025157838A priority patent/JP2025181979A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018512858A 2015-09-11 2016-09-09 角膜の混濁および瘢痕化の予防および治療のための組成物および方法 Active JP6929273B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021130457A JP2021181472A (ja) 2015-09-11 2021-08-10 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
JP2023179927A JP2023179739A (ja) 2015-09-11 2023-10-19 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
JP2025157838A JP2025181979A (ja) 2015-09-11 2025-09-24 角膜の混濁および瘢痕化の予防および治療のための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562217611P 2015-09-11 2015-09-11
US62/217,611 2015-09-11
PCT/US2016/050945 WO2017044743A1 (en) 2015-09-11 2016-09-09 Compositions and methods for prevention and treatment of corneal haze and scarring

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021130457A Division JP2021181472A (ja) 2015-09-11 2021-08-10 角膜の混濁および瘢痕化の予防および治療のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2018526412A JP2018526412A (ja) 2018-09-13
JP2018526412A5 true JP2018526412A5 (cg-RX-API-DMAC7.html) 2019-10-17
JP6929273B2 JP6929273B2 (ja) 2021-09-01

Family

ID=58240852

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018512858A Active JP6929273B2 (ja) 2015-09-11 2016-09-09 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
JP2021130457A Pending JP2021181472A (ja) 2015-09-11 2021-08-10 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
JP2023179927A Pending JP2023179739A (ja) 2015-09-11 2023-10-19 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
JP2025157838A Pending JP2025181979A (ja) 2015-09-11 2025-09-24 角膜の混濁および瘢痕化の予防および治療のための組成物および方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021130457A Pending JP2021181472A (ja) 2015-09-11 2021-08-10 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
JP2023179927A Pending JP2023179739A (ja) 2015-09-11 2023-10-19 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
JP2025157838A Pending JP2025181979A (ja) 2015-09-11 2025-09-24 角膜の混濁および瘢痕化の予防および治療のための組成物および方法

Country Status (7)

Country Link
US (5) US10449234B2 (cg-RX-API-DMAC7.html)
EP (2) EP4417259A3 (cg-RX-API-DMAC7.html)
JP (4) JP6929273B2 (cg-RX-API-DMAC7.html)
AU (3) AU2016320905B2 (cg-RX-API-DMAC7.html)
CA (1) CA2999511C (cg-RX-API-DMAC7.html)
ES (1) ES2983338T3 (cg-RX-API-DMAC7.html)
WO (1) WO2017044743A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6929273B2 (ja) 2015-09-11 2021-09-01 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
JP7287611B2 (ja) * 2018-02-07 2023-06-06 学校法人日本医科大学 改良型アデノ随伴ウイルスベクター
JP2022513178A (ja) 2018-10-09 2022-02-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 受容体アンタゴニストとしての操作された線維芽細胞増殖因子多様体
CN113226467A (zh) * 2018-10-09 2021-08-06 利兰斯坦福初级大学董事会 用于治疗的工程化成纤维细胞生长因子变体与工程化肝细胞生长因子变体的组合
WO2020185689A1 (en) * 2019-03-08 2020-09-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Multilayer drug delivery coating for contact lens
KR20220002271A (ko) * 2019-04-29 2022-01-06 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 간세포 성장인자의 조작된 이량체 단편을 이용한 안구 치료 방법
AU2022272740A1 (en) 2021-05-14 2023-11-02 Claris Biotherapeutics, Inc. Compositions of growth factor for the treatment of eye disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566098B1 (en) * 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
US5703047A (en) * 1992-09-21 1997-12-30 Board Of Regents, The University Of Texas System Methods and treatments for corneal healing with growth factors
US5589451A (en) 1992-09-21 1996-12-31 Board Of Regents, The University Of Texas System Methods and treaments for corneal healing with hepatocyte and keratinocyte growth factors
JP3962097B2 (ja) * 1994-03-18 2007-08-22 敏一 中村 免疫抑制剤による副作用の軽減剤
US20020136721A1 (en) * 1998-02-17 2002-09-26 Schwall Ralph H. Hepatocyte growth factor receptor antagonists and uses thereof
PL343412A1 (en) 1998-03-05 2001-08-13 Senju Pharma Co Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy
US20030148950A1 (en) * 2001-10-09 2003-08-07 Li Xin Kringle domain 1 of human hepatocyte growth factor and uses therefor
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
WO2004019991A2 (en) * 2002-08-30 2004-03-11 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
JP5093783B2 (ja) 2006-04-20 2012-12-12 クリングルファーマ株式会社 Hgf前駆体蛋白質改変体及びその活性型蛋白質
WO2007122976A1 (ja) * 2006-04-20 2007-11-01 Osaka University ポリグルタミン病の治療剤又は発病抑制剤
US20070167935A1 (en) 2007-01-19 2007-07-19 Serdarevic Olivia N Methods and compositions for optimizing the outcomes of refractive laser surgery of the cornea
US9556248B2 (en) * 2010-03-19 2017-01-31 The Board Of Trustees Of The Leland Stanford Junior University Hepatocyte growth factor fragments that function as potent met receptor agonists and antagonists
US9610245B2 (en) 2011-03-14 2017-04-04 Drug Delivery Solutions Limited Ophthalmic composition
US8999938B2 (en) * 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
JP6929273B2 (ja) 2015-09-11 2021-09-01 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 角膜の混濁および瘢痕化の予防および治療のための組成物および方法

Similar Documents

Publication Publication Date Title
US8187608B2 (en) Treatment of Fibrosis related disorders
EP2961426B1 (en) Treatment of central nervous system disorders by intranasal administration of immunoglobulin g
JP2010505946A (ja) 神経再生改善のための補体阻害
US20070059798A1 (en) Polypeptides useful for molecular weight determinations
JP7330510B2 (ja) 非滲出型または萎縮型の黄斑変性にて以前に失われた視力を回復させるための医薬組成物
JP2011528332A (ja) 哺乳動物ベータ・デフェンシンを用いた炎症性疾患の処置
JP2025181979A (ja) 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
Ziebell et al. Nogo presence is inversely associated with shifts in cortical microglial morphology following experimental diffuse brain injury
KR20180096733A (ko) 신경계 및 신경변성 상태의 요법으로서 장기간 작용하는 glf-1r 작용제
CN106661093B (zh) Kv1.3钾通道拮抗剂
Hong et al. Effect of substance P on recovery from laser‐induced retinal degeneration
CN105288598A (zh) 治疗缺氧诱导因子(hif)相关的状况的方法
Vargas et al. Neuroinflammation in glaucoma: soluble tumor necrosis factor alpha and the connection with excitotoxic damage
He et al. C-fiber degeneration enhances alveolar macrophage-mediated IFN-α/β response to respiratory syncytial virus
US20240209036A1 (en) Peptides and methods of use
US20200087362A1 (en) Fusion protein slit2d2(c386s)-hsa and use thereof in prevention and/or treatment of lung inflammation
US20240115667A1 (en) Diphenhydramine and lactoferrin for prevention and treatment of covid-19
CN108078999B (zh) 用于防治缺血性脑卒中的药物组合物及其制备方法和用途
Ahmed et al. A C-terminal peptide from type I interferon protects the retina in a mouse model of autoimmune uveitis
Fajnkuchen et al. Evaluation of a new matrix regenerating agent in patients with Sjögren syndrome and superficial ulcerative keratitis resistant to conventional therapy: A report of 3 cases
CN108721314A (zh) 化合物epz5676及其相关抑制剂在制备防治肺纤维化疾病药物中的用途
BR112022003508A2 (pt) Métodos para restaurar a função lisossômica de células epiteliais de pigmento da retina por ativação de tfeb
JP2021512917A5 (cg-RX-API-DMAC7.html)
US20240307220A1 (en) Combination Therapy to Treat Temperature Sensitive Mutant Tumors
JP4313033B2 (ja) 眼科用治療組成物